Home Microbiology Neuraminidase inhibitor - Influenza Virus inhibitor Zanamivir For research use only.

Zanamivir

Synonyms: GG167,GR 121167X

Zanamivir (GG167,GR 121167X) is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus.

Zanamivir Chemical Structure

Zanamivir Chemical Structure

CAS: 139110-80-8

Selleck's Zanamivir has been cited by 3 Publications

1 Customer Review

Purity & Quality Control

Batch: Purity: 99.97%
99.97

Related compound libraries

Choose Selective Neuraminidase Inhibitors

Biological Activity

Description Zanamivir (GG167,GR 121167X) is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus.
Targets
neuraminidase [1]
In vitro
In vitro

Zanamivir, a novel neuraminidase inhibitor, is effective at decreasing replication of the virus in vitro. [1] Zanamivir results in reduced sensitivity in influenza A/H1N1 variant His274Asn, as well as His274Gly, His274Ser, and His274Gln. [2] Zanamivir blocks influenza neuraminidase and prevents the cleavage of sialic acid residues, thus interfering with progeny virus dispersement within the mucosal secretions and reducing viral infectivity. [3] Zanamivir prevents hemadsorption and fusion of persistently infected cells with uninfected cells. Zanamivir reduces the number (but not the area) of plaques if present only during the adsorption period and reduces plaque area (but not number) if added only after the 90-min adsorption period in plaque assays. Zanamivir also reduces the area of plaques formed by a neuraminidase-deficient variant, confirming that its interference with cell-cell fusion is unrelated to inhibition of neuraminidase activity. Zanamivir has no effect on hemadsorption but does inhibit HA2b-red blood cell fusion, as judged by both lipid mixing and content mixing. [4]
In Vivo
In vivo

Zanamivir reduces lung titers of the virus and decreases morbidity and mortality in a model of lethal challenge in mice. [1]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04597437 Not yet recruiting Dengue Fever George Washington University|Naval Medical Research Center|Clinica de la Costa|Global Disease Research March 1 2024 Early Phase 1
NCT04494412 Recruiting Influenza Human|Arthralgia GlaxoSmithKline November 21 2022 Phase 2
NCT02377401 Completed Influenza Human GlaxoSmithKline April 28 2015 Phase 1
NCT01527110 Completed Influenza Human GlaxoSmithKline January 1 2012 Phase 3
NCT01353768 Completed Infections Respiratory Tract GlaxoSmithKline July 2011 --

Chemical lnformation & Solubility

Molecular Weight 332.31 Formula

C12H20N4O7
CAS No. 139110-80-8 SDF Download Zanamivir SDF
Smiles CC(=O)NC1C(C=C(OC1C(C(CO)O)O)C(=O)O)N=C(N)N
Storage (From the date of receipt)

In vitro
Batch:

Water : 25 mg/mL

DMSO : 2 mg/mL ( (6.01 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Zanamivir | Zanamivir ic50 | Zanamivir price | Zanamivir cost | Zanamivir solubility dmso | Zanamivir purchase | Zanamivir manufacturer | Zanamivir research buy | Zanamivir order | Zanamivir mouse | Zanamivir chemical structure | Zanamivir mw | Zanamivir molecular weight | Zanamivir datasheet | Zanamivir supplier | Zanamivir in vitro | Zanamivir cell line | Zanamivir concentration | Zanamivir nmr